European Medicines Agency greenlights samRNA COVID shot, joining U.S. and Japan in novel technology rollout.

Self-amplifying vaccines use RNA technology engineered to replicate within cells, raising concerns about uncontrolled antigen production, prolonged exposure to spike protein, long-term risks to the immune system, and other health risks. Regular mRNA vaccines, such as Pfizer’s COVID-19 jab, are said to instruct human cells to produce spike protein for a limited time. However, self-replicating mRNA vaccines not only force the body to produce the spike protein within cells but also include mechanisms that make the RNA replicate itself inside the cell, amplifying the production of spike protein over an extended period.

In October, Arcturus Therapeutics received a nearly $1 million grant from the Bill & Melinda Gates Foundation for “vaccine development,” according to the Foundation’s website. The following month, the FDA granted approval for Arcturus Therapeutics’ ARCT-2304, an H5N1 avian influenza “bird flu” samRNA injection. Now Europe, along with the U.S. and Japan, will be deploying this technology apparently with no long-term safety testing. Arcturus Therapeutics is owned by BlackRock, a World Economic Forum partner.

https://jonfleetwood.substack.com/p/europe-authorizes-powder-self-amplifying?